VIVIMIND(TM) granted certificate of free sale as food supplement in Italy - Premarket notification filed in the U.S.
Posted on: Thursday, 16 July 2009, 16:07 CDT
ECUBLENS,
VIVIMIND(TM) is a patented, amino acid, present in some species of algae, to support cognitive function and memory. VIVIMIND(TM) is now available in
U.S. Regulatory Update
With respect to
About BELLUS Health Inc.
BELLUS Health is a global health company focused on the development and commercialization of products to provide innovative health solutions to address critical unmet needs.
To Contact BELLUS Health Inc.
For additional information on BELLUS Health and its drug development programs, please call the
(1) S. Gauthier,
D. Haine, et al. (2009). Effect of Tramiprosate in Patients with
Mild-to-Moderate Alzheimer's Disease: Exploratory Analyses of the MRI
Sub-group of the Alphase Study. Journal of Nutrition, Health and Aging,
Volume 13, Number 6/
Certain statements contained in this news release, other than statements of fact that are independently verifiable at the date hereof, may constitute forward-looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown, many of which are beyond BELLUS Health Inc.'s control. Such risks include but are not limited to: the impact of general economic conditions, general conditions in the pharmaceutical and/or nutraceutical industry, changes in the regulatory environment in the jurisdictions in which the BELLUS Health Group does business, stock market volatility, fluctuations in costs, and changes to the competitive environment due to consolidation, that actual results may vary once the final and quality-controlled verification of data and analyses has been completed, as well as other risks disclosed in public filings of BELLUS Health Inc. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. The reader should not place undue reliance, if any, on any forward-looking statements included in this news release. These statements speak only as of the date made and BELLUS Health Inc. is under no obligation and disavows any intention to update or revise such statements as a result of any event, circumstances or otherwise, unless required by applicable legislation or regulation. Please see the Annual Information Form of BELLUS Health Inc. for further risk factors that might affect the BELLUS Health Group and its business.
CONTACT:
SOURCE BELLUS HEALTH INC.
Source: PR Newswire
Related Articles
- Ronson Reports Sales and Results of Operations In The Third Quarter and Nine Months of 2009
- Genomic Health to Announce Third Quarter 2009 Financial Results and Host Conference Call on Wednesday, November 4, 2009
- 'Health Care Reform Must be Abortion-Free,' says Supreme Knight
- Ronson Reports Sales and Results of Operations in the First Quarter of 2009
- Axiom(R) Audio Warms Audiophiles' Ears This Holiday Season With Free $100 Gift Certificate Offer
- Free Forest Environmental Certification and Marketing of Carbon Credits Offered By Green Energy Resources to Capture Increased Market Share
- Genomic Health, Inc. Announces Third Quarter 2006 Financial Results and Corporate Accomplishments
- Heinz Announces Preliminary Proxy Voting Results; Looks Forward With Confidence to Executing Its Plans to Increase Shareholder Value
- Genomic Health, Inc. Announces Second Quarter 2006 Financial Results and Raises Full-Year Testing Volume and Revenue Guidance
- With This Special Report, Mining Health Risk Assessments for Richer ROI and Results, Expert Panelists Explore the Progressive Evolution of HRAs
 |
 |
User Comments (0)
RSS Feeds